These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32697945)

  • 21. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
    Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
    Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer.
    Fonteyne V; Villeirs G; Lumen N; De Meerleer G
    Radiother Oncol; 2009 Jul; 92(1):42-7. PubMed ID: 19356817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure.
    Wiegner EA; Daly ME; Murphy JD; Abelson J; Chapman CH; Chung M; Yu Y; Colevas AD; Kaplan MJ; Fischbein N; Le QT; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):243-51. PubMed ID: 22019239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late toxicity in the brain after radiotherapy for sinonasal cancer: Neurocognitive functioning, MRI of the brain and quality of life.
    Sharma MB; Jensen K; Amidi A; Eskildsen SF; Johansen J; Grau C
    Clin Transl Radiat Oncol; 2020 Nov; 25():52-60. PubMed ID: 33024844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
    Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
    Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of Life and Radiation-induced Late Toxicity Following Intensity-modulated
    Sprave T; Verma V; Förster R; Schlampp I; Hees K; Bruckner T; Bostel T; El Shafie R; Nicolay NH; Debus J; Rief H
    Anticancer Res; 2018 Aug; 38(8):4953-4960. PubMed ID: 30061275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.
    Ghadjar P; Matzinger O; Isaak B; Behrensmeier F; Stroux A; Rentsch CA; Thalmann GN; Aebersold DM
    Radiother Oncol; 2009 May; 91(2):237-42. PubMed ID: 19167121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses.
    Daly ME; Chen AM; Bucci MK; El-Sayed I; Xia P; Kaplan MJ; Eisele DW
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):151-7. PubMed ID: 17189068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy.
    McDonald MW; Liu Y; Moore MG; Johnstone PA
    Radiat Oncol; 2016 Feb; 11():32. PubMed ID: 26922239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.
    Fonteyne V; De Neve W; Villeirs G; De Wagter C; De Meerleer G
    Radiother Oncol; 2007 Aug; 84(2):156-63. PubMed ID: 17692976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
    Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.
    Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C
    Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-operative intensity-modulated radiotherapy for malignancies of the nasal cavity and paranasal sinuses.
    Dirix P; Nuyts S; Vanstraelen B; Nulens A; Hermans R; Jorissen M; Vander Poorten V; Van den Bogaert W
    Radiother Oncol; 2007 Dec; 85(3):385-91. PubMed ID: 17963908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.